Skip to content

cAPPricorn-1: A clinical trial for people living with Cerebral Amyloid Angiopathy (CAA)

Cerebral Amyloid Angiopathy

cAPPricorn-1 is researching an investigational medication called mivelsiran (Pronounced my-VEL-sur-an) to see if it's safe and effective. Participating in this trial is a chance to contribute to CAA research.

Mivelsiran is a type of medication called a RNAi therapeutic designed to lower the production of a specific protein called amyloid precusor protein (APP)in the brain. this reduction may potential reduce the harmful buildup of harmful amyloid proteins and the brain's blood vessels and potentially slow down the worsening of CAA.

During the treatment period of cAPPricorn-1, you will have study visits about once every 3 months for a total of 12 visits over 2 years. With the optional 18-month open-label extension period, you would have an additional 5 study visits. There will also be a follow-up visit 1 year after the end of treatment, whether it be the double-blind treatment period or the open-label
extension period.

null

Participation Requirements

  • Sex:

    Male, Female, Intersex
  • Eligible Ages:

    50 to 90

Participation Criteria

Inclusion Criteria:
There are 2 type of CAA: Sporadic CAA or Dutch-type CAA. You must have a diagnosis of either to participate.
In addition, specific to each type, people who can participate are people:
With Sporadic CAA who are:
-50 years of age or older
-Have recedived a diagnosis of CAA from their doctor

With Dutch-type CAA who are:
-30 years of age or older
-Have known gene mutation for Dutch-typeCAA

Additional criteria are assessed by the study team.

Exclusion Criteria:
People not eligible:
-People who have moderate to severe Alzheimer's disease
-History of previous intracranial bleeding (brain bleed) within 3 months
-no anti-platelet therapy or anti-coagulant therapy (blood thinners). Aspirin is allowed.
-must be able to have a lumbar puncture (spinal tap). No spinal problems.
-No significant heart problems
-No high blood pressure with a systolic greater than 150mmHg and diastolic greater than 90mmHg
-No attempted suicide

Other additional exclusions will be assessed by the study team

Study Location

Clinical Trial Site
Clinical Trial Site
Moncton, New Brunswick
Canada

Contact Study Team

Clinical Trial Site
Clinical Trial Site
Montreal, Quebec
Canada

Contact Study Team

Clinical Trial Site
Clinical Trial Site
Richmond, British Columbia
Canada

Contact Study Team

Clinical Trial Site
Clinical Trial Site
Ottawa, Ontario
Canada

Contact Study Team

Clinical Trial Site
Clinical Trial Site
Victoria, British Columbia
Canada

Contact Study Team

Clinical Trial Site
Clinical Trial Site
Toronto, Ontario
Canada

Contact Study Team

Clinical Trial Site
Clinical Trial Site
Calgary, Alberta
Canada

Contact Study Team

Clinical Trial Site
Clinical Trial Site
Hamilton, Ontario
Canada

Contact Study Team

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contact Study Team

Clinical Trial Site
Clinical Trial Site
Calgary, Alberta
Canada

Contact Study Team

Clinical Trial Site
Clinical Trial Site
Ottawa, Ontario
Canada

Contact Study Team

Clinical Trial Site
Clinical Trial Site
Moncton, New Brunswick
Canada

Contact Study Team

Clinical Trial Site
Clinical Trial Site
Hamilton, Ontario
Canada

Contact Study Team

Clinical Trial Site
Clinical Trial Site
Kelowna, British Columbia
Canada

Contact Study Team

Clinical Trial Site
Clinical Trial Site
Toronto, Ontario
Canada

Contact Study Team

Study Sponsored By
Alnylam Pharmaceuticals
Participants Required
More Information
Study ID: NCT06393712